PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Levels of platelet reactivity in patients on Dual Antiplatelet Therapy (DAPT) can be
influenced by concomitant treatment with medications (i.e. statins) that inhibit the CYP3A4
system involved in the activation of clopidogrel. Atorvastatin and simvastatin are
metabolized by CYP3A4. Pitavastatin, unlike other statins, is little metabolized, most of the
dose being excreted unchanged in bile, and biotransformation through the cytochrome P450
system is minimal. Indeed, pitavastatin's cyclopropyl group diverts the drug away from
metabolism by CYP3A4 and allows only a small amount of clinically insignificant metabolism by
CYP2C9.
The primary objective of this study is to compare the pharmacodynamic effects of a
CYP3A4-metabolized statin (atorvastatin) versus a non-CYP3A4-metabolized statin
(pitavastatin) in patients showing high platelet reactivity while on DAPT.